| Name | Title | Contact Details |
|---|
LabConnect is a global provider of clinical trial laboratory services, established in 2002 and based in Seattle, Washington. The company specializes in central laboratory solutions and functional service provider (FSP) support, partnering with pharmaceutical, biotechnology, and clinical research organizations. LabConnect has successfully managed over 1,900 clinical studies across 93 countries, emphasizing agility and innovation through a network of more than 30 laboratory locations worldwide. The company offers a range of services, including project management, a global testing network with over 10,000 validated tests, and comprehensive logistics and biorepository solutions. LabConnect also provides bioanalytical expertise and customized staffing for scientific project management. Its product offerings include customized lab kits for trial sites and integrated data management systems for real-time analytics. With a strong client portfolio that includes major pharmaceutical firms, LabConnect is positioned as a reliable partner for complex clinical trials.
Protagonist Therapeutics is a biotechnology company pursuing the discovery and development of target oral peptides as well differentiated alternatives to antibodies, and also as new chemical entities (NCEs) against those targets and life threatening diseases for which suitable small molecule and/or biologic options are not available. Peptides typically suffer from limitations of poor proteolytic stability and therefore find scarce therapeutic utility that is largely limited to ‘injectable drugs’. Protagonist’s technology platform is aimed at overcoming these restrictions and expanding the scope of peptide therapeutics to address unmet needs. Specific emphasis is placed on identifying ‘orally stable’ scaffolds and/or engineering oral stability characteristics onto them. The platform has been optimized over the years and involves synergistic integration of rational drug design, diversity oriented computational tools, phage display libraries, recombinant peptide expression, ex vivo oral stability methods, and peptide/medicinal chemistry techniques. This activity has led to the identification of ‘privileged scaffolds’ with favorable oral stability characteristics. Furthermore, the technology platform is well suited both for de novo discovery against a target and optimization around a given chemical starting point.
Hawaii Chitopure is a Honolulu, HI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Janpix is discovering and developing monovalent small molecule degraders of Signal Transducer and Activator of Transcription (“STAT”) proteins. Most members of this family of transcription factors have been known for some time and the relevance of STAT3 & STAT5, in particular, in certain cancers is well validated. Although disrupting the function of STAT proteins is very challenging, Janpix has developed new chemistry to address this complex problem.
Medcura, Inc. has developed an advanced wound care platform that can be used across a broad spectrum of clinical and non-clinical settings. By making molecular modifications to natural biopolymers, Medcura`s patented approach provides rapid hemostasis in a clean, safe healing environment. The company has achieved milestones such as 3 FDA Clearances, 6 issued patents, and 7 peer-reviewed publications.